Health & Medicinearticle2026-11-07

Long COVID: A Modified Delphi Consensus on Definition, Burden, Diagnosis and Management in Southeast Asia

Open access0 citations

Abstract

Long COVID is a heterogeneous post-infectious condition following acute severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. Ongoing uncertainty around its definition, burden, diagnosis and management complicates clinical recognition and care in Southeast Asia. A modified Delphi consensus study was conducted with twelve experts from six Southeast Asian countries to develop regional guidance on long COVID. Consensus was predefined as ≥ 80% agreement, corresponding to at least 10 of 12 experts selecting the same response in multiple-choice questions or indicating agreement on Likert-scale questions (e.g. agree/strongly agree, most important/more important, relevant/highly relevant). Questions that reached consensus were removed from the subsequent round, while unresolved questions were revised, consolidated, or expanded. In the final round, a post hoc descriptive category, ‘moderate endorsement’, was applied to Likert-scale questions that had not reached consensus, with ‘important’ as the midpoint category of the five-point importance scale (‘most important’ to ‘least important’), to capture responses judged important but falling short of the consensus threshold. Consensus was reached for all ‘definition’, ‘burden’ and ‘management’ theme questions and most ‘diagnosis’ questions. Experts defined long COVID as unexplained symptoms persisting for > 3 months after SARS-CoV-2 infection, distinct from post-acute COVID-19, with no minimum severity threshold requirement. Long COVID was recognised as affecting approximately 6%–10% of individuals after SARS-CoV-2 infection, consistent with published WHO and KSID estimates; clinical evaluation and symptom-guided testing were recommended for its diagnosis. Hospitalisation during acute COVID-19 was identified as a risk factor for developing long COVID. The experts recommended multidisciplinary, symptom-directed care, rehabilitation, pacing and follow-up. Vaccination and reinfection prevention were supported as important long COVID risk-reduction strategies, and early antiviral treatment should be considered to prevent severe acute illness and hospitalisation in high-risk individuals. Consensus was not reached on the past medical history required for diagnosis; moderate endorsement was observed for booster status, absence of early antiviral treatment, pre-COVID health assessment and standardised patient-reported outcome tools. This Delphi study provides a practical regional consensus framework for long COVID in Southeast Asia.

// Source

View paper (DOI)Open access versionOpenAlexPulmonary TherapyPublished 2026-11-07

Authors: Erlina Burhan, Huck Chin Chew, Fathiyah Isbaniah, Sathya Rao Jogulu, Chee Loon Leong, Hoe Nam Leong, Weerawat Manosuthi, Nguyen Viet Nhung, Arthur Dessi Roman, MICHELLE ANGELA TAN-REYES, Vu Le-Thuong, Phunsup Wongsurakiat, Ervin Cheong, Bulent Nuri Taysi, Karan B. Thakkar

Institutions: University of Medicine and Pharmacy at Ho Chi Minh City, Siriraj Hospital, Mahidol University, University of Indonesia, Pfizer (United States), Research Institute for Tropical Medicine, Hospital Kuala Lumpur, University Medical Center HCMC, Ministry of Public Health, Department of Disease Control, Bamrasnaradura Infectious Diseases Institute, Department of Health, Mount Elizabeth Novena Hospital, VNU University of Medicine and Pharmacy, Respiratory Programmatic Implementation and Research Institute, Asian Hospital and Medical Center